BioAdaptives Appoints New Director, Officer Compensation Disclosed
Ticker: BDPT · Form: 8-K · Filed: May 22, 2024 · CIK: 1575142
| Field | Detail |
|---|---|
| Company | Bioadaptives, INC. (BDPT) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, officer-compensation
TL;DR
BioAdaptives swapped a director and is talking about exec pay.
AI Summary
BioAdaptives, Inc. announced on May 20, 2024, the departure of Director David L. Miller and the appointment of Dr. Robert L. Smith as a new director. The company also disclosed compensatory arrangements for certain officers, though specific details and dollar amounts were not provided in this filing.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in directorship and compensation arrangements can introduce uncertainty about future company direction and financial performance.
Key Players & Entities
- BioAdaptives, Inc. (company) — Registrant
- David L. Miller (person) — Departing Director
- Dr. Robert L. Smith (person) — Appointed Director
- May 20, 2024 (date) — Event Date
FAQ
Who is the new director appointed to the board of BioAdaptives, Inc.?
Dr. Robert L. Smith was appointed as a new director.
Who has departed from the board of BioAdaptives, Inc.?
Director David L. Miller has departed from the board.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated May 20, 2024.
What are the primary items disclosed in this 8-K filing?
The filing concerns the departure of a director, election of a director, appointment of officers, and compensatory arrangements of certain officers, along with Regulation FD disclosures and financial statements/exhibits.
What is the principal executive office address for BioAdaptives, Inc.?
The principal executive office is located at 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-22 06:00:41
Filing Documents
- bdpt_8k.htm (8-K) — 20KB
- bdpt_ex991.htm (EX-99.1) — 10KB
- bdpt_8kimg1.jpg (GRAPHIC) — 5KB
- 0001640334-24-000864.txt ( ) — 160KB
- bdpt-20240520.xsd (EX-101.SCH) — 6KB
- bdpt-20240520_lab.xml (EX-101.LAB) — 13KB
- bdpt-20240520_cal.xml (EX-101.CAL) — 1KB
- bdpt-20240520_pre.xml (EX-101.PRE) — 8KB
- bdpt-20240520_def.xml (EX-101.DEF) — 2KB
- bdpt_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The Company issued a press release on May 21, 2024, announcing the departure of Dr .Edward Jacobs, Jr and Mr Robert Ellis and the appointment of Mr. James Keener as the Company's Director and CEO. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release 2 SIGNATURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. May 22, 2024 BioAdaptives, Inc. /s/ James Keener James Keener Director and CEO 3